Investors

Overview

Corporate Profile

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently we are developing our proprietary Chimeric Antigen Receptor (CAR) engineered NK cells (CAR-NK) technology, which we licensed from the laboratories of Drs. Michael Caligiuri and Jianhua Yu at the City of Hope National Medical Center (COH).

Corporate Presentation

Press Releases

CytoImmune Therapeutics Establishes Operations in Puerto Rico to Develop Novel Cancer Immunotherapy Products

SAN JUAN, Puerto Rico, March 1, 2021 /PRNewswire/ -- Invest Puerto Rico (InvestPR), the Island's economic development organization, and the Puerto Rico Department of Economic Development […]

Invest Puerto Rico elevates the Island’s role as a global bioscience R&D and manufacturing hub attracting two major life-critical investments, $228M in new activity

- CytoImmune Therapeutics and Biosimilar Sciences US will soon call Puerto Rico home and engage in cancer immunotherapy solutions and a COVID-19 vaccine, respectively - Both […]

Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors

Michael A. Caligiuri, MD joins Cytovia Scientific Advisory Board NEW YORK and MONROVIA, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (“Cytovia”), an emerging […]

Events Presentation

Press Releases

Events Presentation

Lorem Ipsum Title Event Presentation 3

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud […]

Lorem Ipsum Title Event Presentation 2

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud […]